Ascentage pharma signs option agreement with takeda to enter into exclusive global license for olverembatinib, a third-generation bcr-abl tyrosine kinase inhibitor (tki)

Ascentage pharma has executed an exclusive option to license global rights to olverembatinib worldwide other than china and a few other areas. ascentage pharma to receive an option payment of 100 million usd upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion usd, and double-digit royalties on annual sales additionally, takeda will purchase a minority interest in ascentage pharma rockville, md.
TAK Ratings Summary
TAK Quant Ranking